{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:34Z","timestamp":1786116574589,"version":"build-2736575974"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Cancer immunotherapies, including immune checkpoint inhibitors and adoptive cell transfer, have shown great efficacy and promise against hematological malignancies. However, the value of these therapies remains inconclusive in the context of solid cancers and is limited by several obstacles, including difficulty in identifying cancer-specific antigens, limited immune cell trafficking and infiltration into tumors, and the immunosuppressive effects of the tumor microenvironment. To further optimize the clinical effects of immunotherapies, many studies have focused on modifying metabolic programs, especially glycosylation, in cells. Glycosylation, which adds a diversity of carbohydrate structures (glycans) to surface molecules on virtually all cells, regulates stimulatory and inhibitory signaling pathways. Therefore, modification of key glycosylation pathways represents a logical approach for the development of new therapeutic strategies for treating solid cancers. We review how specific glycans regulate the anticancer activities of immune cells and immunosuppressive effects of cancer cells in cancer immunotherapy. In addition, we highlight T cells with NK cell properties\n                    <jats:italic>ex vivo<\/jats:italic>\n                    primed by N-glycosylation inhibitor and their advantageous functions for treatments of solid cancers.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1824624","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:35:25Z","timestamp":1786016125000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Developing immunotherapies through glycosylation reprogramming to combat solid cancers"],"prefix":"10.3389","volume":"17","author":[{"given":"Toshihiko","family":"Toyofuku","sequence":"first","affiliation":[{"name":"Department of Immunology and Molecular Medicine, Graduate School of Medicine, The Center of Medical Innovation and Translational Research, Osaka University","place":["Suita, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University","place":["Osaka, Japan"]},{"name":"Laboratory of Immunopathology, WPI Immunology Frontier Research Center, Osaka University","place":["Suita, Osaka, Japan"]},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University","place":["Suita, Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"Immunol Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.201006432011512c","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: Bright future or dark reality","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00655-2","article-title":"Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2026.14266","article-title":"CAR-T cell therapy in cancer immunotherapy - Biology, clinical successes, and emerging challenges: A review","volume":"26","author":"Bedada","year":"2026","journal-title":"Biomol BioMed"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(02)01139-x","article-title":"Molecular and functional profiling of memory CD8 T cell differentiation","volume":"111","author":"Kaech","year":"2002","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.11.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature08097","article-title":"Enhancing CD8 T-cell memory by modulating fatty acid metabolism","volume":"460","author":"Pearce","year":"2009","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13827","article-title":"Reinforce the antitumor activity of CD8(+) T cells via glutamine restriction","volume":"109","author":"Nabe","year":"2018","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.928","article-title":"Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review)","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol Lett"},{"key":"B17","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrc2255","article-title":"A microenvironmental model of carcinogenesis","volume":"8","author":"Gatenby","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg's contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1193494","article-title":"The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes","volume":"330","author":"Levine","year":"2010","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2468","article-title":"Hypoxia, HIF1 and glucose metabolism in the solid tumour","volume":"8","author":"Denko","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioteChadv.2023.108184","article-title":"Understanding glycosylation: Regulation through the metabolic flux of precursor pathways","volume":"67","author":"Scheper","year":"2023","journal-title":"Biotechnol Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01074-1","article-title":"Immune regulatory networks coordinated by glycans and glycan-binding proteins in autoimmunity and infection","volume":"20","author":"Pinho","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/glycob\/cww086","article-title":"Biological roles of glycans","volume":"27","author":"Varki","year":"2017","journal-title":"Glycobiology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.11.003","article-title":"Translating the 'Sugar Code' into immune and vascular signaling programs","volume":"42","author":"Cerliani","year":"2017","journal-title":"Trends Biochem Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2536","article-title":"Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation","volume":"9","author":"Rabinovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1749-6632.2011.06391.x","article-title":"Interleukin-2, interleukin-7, T cell-mediated autoimmunity, and N-glycosylation","volume":"1253","author":"Grigorian","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/ncomms1333","article-title":"Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis","volume":"2","author":"Mkhikian","year":"2011","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/35055582","article-title":"Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation","volume":"409","author":"Demetriou","year":"2001","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.immuni.2018.01.006","article-title":"Interleukin-10 directly inhibits CD8(+) T cell function by enhancing N-glycan branching to decrease antigen sensitivity","volume":"48","author":"Smith","year":"2018","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103791","article-title":"The role of N-glycans in regulatory T cells in autoimmunity","volume":"24","author":"Carneiro","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00987","article-title":"Distinctive surface glycosylation patterns associated with mouse and human CD4(+) regulatory T cells and their suppressive function","volume":"8","author":"Cabral","year":"2017","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwv097","article-title":"Sialic acids in cancer biology and immunity","volume":"26","author":"Pearce","year":"2016","journal-title":"Glycobiology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00839.x","article-title":"Functional roles of N-glycans in cell signaling and cell adhesion in cancer","volume":"99","author":"Zhao","year":"2008","journal-title":"Cancer Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/187152008783330833","article-title":"Biological modulation by lectins and their ligands in tumor progression and metastasis","volume":"8","author":"Nakahara","year":"2008","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.130.2.383","article-title":"Reduced contact-inhibition and substratum adhesion in epithelial cells expressing GlcNAc-transferase V","volume":"130","author":"Demetriou","year":"1995","journal-title":"J Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1126\/science.1102109","article-title":"Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis","volume":"306","author":"Partridge","year":"2004","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.049","article-title":"Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation","volume":"129","author":"Lau","year":"2007","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.23.13811","article-title":"Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis","volume":"271","author":"Yoshimura","year":"1996","journal-title":"J Biol Chem"},{"key":"B41","article-title":"Increased expression of highly branched N-glycans at cell surface is correlated with the Malignant phenotypes of mouse tumor cells","volume":"57","author":"Asada","year":"1997","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m413532200","article-title":"Deletion of mouse embryo fibroblast N-acetylglucosaminyltransferase V stimulates alpha5beta1 integrin expression mediated by the protein kinase C signaling pathway","volume":"280","author":"Guo","year":"2005","journal-title":"J Biol Chem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.2c00723","article-title":"Molecular recognition of GalNAc in mucin-type O-glycosylation","volume":"56","author":"Sanz-Martinez","year":"2023","journal-title":"Acc Chem Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00600","article-title":"Regulation of T cell trafficking by enzymatic synthesis of O-glycans","volume":"8","author":"Hobbs","year":"2017","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143536","article-title":"Aberrant glycosylation as immune therapeutic targets for solid tumors","volume":"15","author":"Matsumoto","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174248","article-title":"Aberrant sialylation in cancer: Therapeutic opportunities","volume":"14","author":"Munkley","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110641","article-title":"Sialic acids in cancer biology and immunity-recent advancements","volume":"301","author":"van Vliet","year":"2025","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41467-021-21550-4","article-title":"Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091241","article-title":"The diverse contributions of fucose linkages in cancer","volume":"11","author":"Keeley","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.027","article-title":"Blockage of core fucosylation reduces cell-surface expression of PD-1 and promotes anti-tumor immune responses of T cells","volume":"20","author":"Okada","year":"2017","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182395","article-title":"Development of immune checkpoint therapy for cancer","volume":"216","author":"Fritz","year":"2019","journal-title":"J Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.04.002","article-title":"Post-translational regulations of PD-L1 and PD-1: mechanisms and opportunities for combined immunotherapy","volume":"85","author":"Dai","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-19-3133","article-title":"Targeting glycosylated PD-1 induces potent antitumor immunity","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.93806","article-title":"Glycosylation targeting: a paradigm shift in cancer immunotherapy","volume":"20","author":"Ren","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B61","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.3.1352","article-title":"CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression","volume":"165","author":"Carreno","year":"2000","journal-title":"J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4049\/jimmunol.175.2.996","article-title":"Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation","volume":"175","author":"Darlington","year":"2005","journal-title":"J Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/mc.23170","article-title":"Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation","volume":"59","author":"Kim","year":"2020","journal-title":"Mol Carcinog"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114851119","article-title":"D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","article-title":"Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1","volume":"33","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005278","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cells13090725","article-title":"State of the art in CAR-T cell therapy for solid tumors: is there a sweeter future","volume":"13","author":"Amoros-Perez","year":"2024","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.07.006","article-title":"Targeting glycans for CAR therapy: the advent of sweet CARs","volume":"30","author":"Raglow","year":"2022","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12929-021-00746-2","article-title":"Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy","volume":"28","author":"Chiang","year":"2021","journal-title":"J BioMed Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid Malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/1044-579x(95)90005-5","article-title":"Augmenting the immunogenicity of carbohydrate tumor antigens","volume":"6","author":"Livingston","year":"1995","journal-title":"Semin Cancer Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266980","article-title":"BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity","volume":"17","author":"Hickman","year":"2022","journal-title":"PLoS One"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910577","article-title":"Glycan-lectin interactions in cancer and viral infections and how to disrupt them","volume":"22","author":"Kremsreiter","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B83","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.9b01015","article-title":"Antibodies from lampreys as smart anti-glycan reagents (SAGRs): perspectives on their specificity, structure, and glyco-genomics","volume":"59","author":"McKitrick","year":"2020","journal-title":"Biochemistry"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005891","article-title":"Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma","volume":"11","author":"McKenna","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.smim.2015.11.003","article-title":"Reprogramming the tumor microenvironment to enhance adoptive cellular therapy","volume":"28","author":"Beavis","year":"2016","journal-title":"Semin Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01217","article-title":"Next-generation manufacturing protocols enriching T(SCM) CAR T cells can overcome disease-specific T cell defects in cancer patients","volume":"11","author":"Arcangeli","year":"2020","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653605","article-title":"Control of T cell metabolism by cytokines and hormones","volume":"12","author":"Bishop","year":"2021","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-022-01255-x","article-title":"Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells","volume":"15","author":"Huang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02354-4","article-title":"Comparison of IL-2 vs IL-7\/IL-15 for the generation of NY-ESO-1-specific T cells","volume":"68","author":"Gong","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10510","article-title":"Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95103","article-title":"Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy","volume":"2","author":"Klebanoff","year":"2017","journal-title":"JCI Insight"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.3086.3086","article-title":"Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy","volume":"5","author":"Urak","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3Kdelta inhibition enhances the antitumor fitness of adoptively transferred CD8(+) T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011597","article-title":"PI3Kdelta\/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33212","article-title":"Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients","volume":"148","author":"Fan","year":"2021","journal-title":"Int J Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell Malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1172\/jci86437","article-title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","volume":"126","author":"Kagoya","year":"2016","journal-title":"J Clin Invest"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pcmr.12267","article-title":"Is it time to test biguanide metformin in the treatment of melanoma","volume":"28","author":"Cerezo","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900937","article-title":"Blockade of N-Glycosylation promotes antitumor immune response of T cells","volume":"204","author":"Sasawatari","year":"2020","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.09.003","article-title":"2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy","volume":"355","author":"Zhang","year":"2014","journal-title":"Cancer Lett"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J Clin Invest"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300618","article-title":"Efficacy against lung cancer is augmented by combining aberrantly N-Glycosylated T cells with a chimeric antigen receptor targeting Fragile X Mental Retardation 1 Neighbor","volume":"212","author":"Toyofuku","year":"2024","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cytogfr.2017.06.003","article-title":"Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells","volume":"36","author":"Cappuzzello","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229540","article-title":"How can Cytokine-induced killer cells overcome CAR-T cell limits","volume":"14","author":"Cappuzzello","year":"2023","journal-title":"Front Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032743","article-title":"Natural killer T-like cells: Immunobiology and role in disease","volume":"24","author":"Almeida","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00530","article-title":"Functionally diverse NK-like T cells are effectors and predictors of successful aging","volume":"7","author":"Michel","year":"2016","journal-title":"Front Immunol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.09.010","article-title":"Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation","volume":"45","author":"Lo","year":"2008","journal-title":"Mol Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020375","article-title":"Design and characterization of an \"All-in-One\" lentiviral vector system combining constitutive anti-G(D2) CAR expression and inducible cytokines","volume":"12","author":"Zimmermann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.11","article-title":"CAR T cells targeting alpha(v)beta(3) integrin are effective against advanced cancer in preclinical models","volume":"1","author":"Wallstabe","year":"2018","journal-title":"Adv Cell Gene Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.657868","article-title":"Chimeric antigen receptor T cells targeting integrin alphavbeta6 expressed on cholangiocarcinoma cells","volume":"11","author":"Phanthaphol","year":"2021","journal-title":"Front Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1042\/bst20150249","article-title":"The integrin alphavbeta6: a novel target for CAR T-cell immunotherapy","volume":"44","author":"Whilding","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.20265","article-title":"Integrin alpha(v)beta(3)-targeted cancer therapy","volume":"69","author":"Liu","year":"2008","journal-title":"Drug Dev Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1080\/07388551.2021.1988509","article-title":"Addressing the obstacles of CAR T cell migration in solid tumors: Wishing a heavy traffic","volume":"42","author":"Safarzadeh Kozani","year":"2022","journal-title":"Crit Rev Biotechnol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","article-title":"Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1038\/s41467-021-26352-2","article-title":"Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation","volume":"12","author":"Laine","year":"2021","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/ni.f.213","article-title":"Orchestrating the orchestrators: Chemokines in control of T cell traffic","volume":"9","author":"Bromley","year":"2008","journal-title":"Nat Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585214","article-title":"Immunotherapy targeting myeloid-derived suppressor cells (MDSCs) in tumor microenvironment","volume":"11","author":"Gao","year":"2020","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-derived suppressor cells in tumors: From mechanisms to antigen specificity and microenvironmental regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaf8566","article-title":"Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling","volume":"9","author":"Rutherford","year":"2016","journal-title":"Sci Signal"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2025.04.027","article-title":"Glycosylation-driven programs coordinate immunoregulatory and pro-angiogenic functions of myeloid-derived suppressor cells","volume":"58","author":"Blidner","year":"2025","journal-title":"Immunity"},{"key":"B132","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729735","article-title":"Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy","volume":"20","author":"Chou","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00434-9","article-title":"Strategies to enhance CAR-T persistence","volume":"10","author":"Liu","year":"2022","journal-title":"biomark Res"},{"key":"B140","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: Current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coche.2017.11.006","article-title":"CD8(+) T cells and NK cells: Parallel and complementary soldiers of immunotherapy","volume":"19","author":"Rosenberg","year":"2018","journal-title":"Curr Opin Chem Eng"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): Their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017","article-title":"CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions","volume":"111","author":"Hunter","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1172\/jci65899","article-title":"Interactions between Siglec-7\/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance","volume":"124","author":"Jandus","year":"2014","journal-title":"J Clin Invest"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1172\/jci120612","article-title":"Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells","volume":"128","author":"Stanczak","year":"2018","journal-title":"J Clin Invest"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.10.002","article-title":"Macrophage immunotherapy: Overcoming impediments to realize promise","volume":"43","author":"Sly","year":"2022","journal-title":"Trends Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: Recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14343","article-title":"The roles of CSFs on the functional polarization of tumor-associated macrophages","volume":"285","author":"Jeannin","year":"2018","journal-title":"FEBS J"},{"key":"B151","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8946","article-title":"Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors","volume":"16","author":"Xu","year":"2018","journal-title":"Oncol Lett"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltac005","article-title":"Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer","volume":"2","author":"Rossetti","year":"2022","journal-title":"Immunother Adv"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01643","article-title":"Current concepts of antigen cross-presentation","volume":"9","author":"Embgenbroich","year":"2018","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1039\/d3bm01746j","article-title":"Preparation of glycopeptide-modified pH-sensitive liposomes for promoting antigen cross-presentation and induction of antigen-specific cellular immunity","volume":"12","author":"Yuba","year":"2024","journal-title":"Biomater Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T11:35:28Z","timestamp":1786016128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":157,"alternative-id":["10.3389\/fimmu.2026.1824624"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1824624","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1824624"}}